News Overview

Zydus Lifesciences announced it's Q3 FY25 and net profit grew by 30% YoY.

As part of the contract, debentures shall have a tenure of 3,651 days (approx. 10 years) and shall be listed on the Wholesale Debt Market

However, the company stated that its revenue from operations registered a growth of 66.90% to ₹534.70 Crore in Q3FY25.

The deal is aimed at improving operational efficiency, expanding capabilities, and fuel innovation in the maritime sector.

Top gainers in Sensex include Nestle (1.11%), TCS (0.27%), HCL Tech (0.27%), ITC (0.23%).

The EBITDA increased to ₹1,211 crore (12.8%), from ₹1,114 crore (12%) in Q3 FY24, while keeping double-digit EBITDA intact for the 8th consecutive quarter. 

The board of directors declared an interim dividend of 150% (₹1.50 per equity share, on a face value of ₹1) for the financial year ending March 31, 2025.

Despite positive net inflows; equity funds experienced the bulk of the price depletion in January 2025

At 3.0%, the US consumer inflation is a full 100 bps above the Fed target of 2.0%, reducing further rate cut hopes

The IIP growth for December was subdued at 3.22%, but previous revisions have been a mixed bag